ArticleCancer innovation2024

Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: A Bayesian network meta-analysis.

Lixi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.